{"id":"alkylating-based-chemotherapy","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Myelosuppression"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Hair loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Alkylating agents work by adding an alkyl group to the DNA molecule, which interferes with DNA replication and transcription, ultimately leading to cell death.","oneSentence":"Alkylating agent that interferes with DNA replication","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T05:52:30.141Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various cancers"}]},"trialDetails":[{"nctId":"NCT06325709","phase":"PHASE1, PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":"Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease","enrollment":10},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT06851767","phase":"PHASE1, PHASE2","title":"Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-05-09","conditions":"X-linked Severe Combined Immunodeficiency, X-SCID, XSCID","enrollment":18},{"nctId":"NCT03301350","phase":"PHASE2","title":"Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-11-07","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":29},{"nctId":"NCT06937905","phase":"PHASE3","title":"Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2026-02-06","conditions":"Neuroendocrine Carcinoma","enrollment":129},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT06829771","phase":"PHASE1, PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":"Diffuse Large B Cell Lymphoma","enrollment":90},{"nctId":"NCT07214987","phase":"PHASE2","title":"PDT For Induction Therapy For Head And Neck Cancer","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-09","conditions":"Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":26},{"nctId":"NCT07318805","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-16","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer","enrollment":260},{"nctId":"NCT04900792","phase":"PHASE1","title":"A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bryan Allen","startDate":"2023-02-28","conditions":"Glioblastoma, Glioblastoma Multiforme","enrollment":17},{"nctId":"NCT05052957","phase":"PHASE2","title":"hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)","status":"RECRUITING","sponsor":"Leland Metheny","startDate":"2023-01-20","conditions":"Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma","enrollment":16},{"nctId":"NCT03217097","phase":"NA","title":"MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-10-16","conditions":"Neuroendocrine Tumors","enrollment":116},{"nctId":"NCT01189643","phase":"EARLY_PHASE1","title":"Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-08","conditions":"Sarcoma, Desmoplastic Small Round Cell Tumor (DSRCT)","enrollment":15},{"nctId":"NCT07120984","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma","status":"NOT_YET_RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2026-01-30","conditions":"Glioma","enrollment":52},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT04762069","phase":"PHASE2","title":"A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"CNS Pharmaceuticals, Inc.","startDate":"2021-05-18","conditions":"Glioblastoma Multiforme, Adult","enrollment":210},{"nctId":"NCT06493552","phase":"PHASE2, PHASE3","title":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors","status":"RECRUITING","sponsor":"Vasgene Therapeutics, Inc","startDate":"2025-03-15","conditions":"Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma","enrollment":700},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT06421610","phase":"PHASE1","title":"OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2023-09-15","conditions":"Malignant Pleural Effusion, Pleural Neoplasms, Quality of Life","enrollment":20},{"nctId":"NCT02013167","phase":"PHASE3","title":"Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Amgen","startDate":"2014-01-03","conditions":"Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia","enrollment":405},{"nctId":"NCT05883852","phase":"PHASE3","title":"EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-07","conditions":"HER2 Positive Early Breast Cancer","enrollment":1406},{"nctId":"NCT02951156","phase":"PHASE3","title":"Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-12-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":29},{"nctId":"NCT00245037","phase":"PHASE1, PHASE2","title":"Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2005-06","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":147},{"nctId":"NCT02772107","phase":"PHASE2, PHASE3","title":"Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2015-12","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":132},{"nctId":"NCT01397149","phase":"PHASE1, PHASE2","title":"Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)","status":"TERMINATED","sponsor":"University of Ulm","startDate":"2011-10","conditions":"Chronic Lymphocytic Leukemia, Thrombocytopenia","enrollment":4},{"nctId":"NCT00002680","phase":"PHASE2","title":"Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"1994-02","conditions":"Breast Cancer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Alkylating-based chemotherapy","genericName":"Alkylating-based chemotherapy","companyName":"Hospices Civils de Lyon","companyId":"hospices-civils-de-lyon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alkylating agent that interferes with DNA replication Used for Various cancers.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}